Literature DB >> 7526518

Evaluation and results of treatments for prostatism.

D E Neal.   

Abstract

Men with symptoms of prostatism form a heterogenous group. The best treatment of proven obstruction or retention in fit men remains transurethral prostatectomy (TURP). Men presenting with symptoms of prostatism may have bladder outflow obstruction, detrusor instability or weak bladder contraction leading to low pressure/low flow voiding so it is perhaps not surprising that only 75% of men selected for TURP purely on the basis of symptoms have a good outcome. Pressure flow studies are the only precise method of diagnosing outflow obstruction. The problem of accurately diagnosing obstruction before treatment is started applies particularly to trials of new treatments such as lasers, high energy focused ultrasound and drugs. Laser treatment is producing short term results that are slightly inferior to TURP but may have less morbidity. The role of conservative treatment is important in selected men. Men who have severe intercurrent illness may be treated by means of intra-prostatic stents. In order to accurately assess a new treatment it is necessary to determine the short-term mortality, the morbidity, complication rate and outcome as well as the cost-effectiveness, long-term outcome and patient preference. These conditions have not yet been met for any of the new treatments for prostatism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526518     DOI: 10.1007/bf00310993

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  24 in total

1.  Memokath: a second generation of intraprostatic spirals.

Authors:  A L Poulsen; J Schou; H Ovesen; J Nordling
Journal:  Br J Urol       Date:  1993-09

Review 2.  Nonoperative management of benign prostatic hyperplasia.

Authors:  H Lepor
Journal:  J Urol       Date:  1989-06       Impact factor: 7.450

3.  Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia.

Authors:  N P Roos; J E Wennberg; D J Malenka; E S Fisher; K McPherson; T F Andersen; M M Cohen; E Ramsey
Journal:  N Engl J Med       Date:  1989-04-27       Impact factor: 91.245

4.  Relationship between voiding pressures, symptoms and urodynamic findings in 253 men undergoing prostatectomy.

Authors:  D E Neal; R A Styles; P H Powell; J Thong; P D Ramsden
Journal:  Br J Urol       Date:  1987-12

5.  The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients.

Authors:  P H Abrams; D J Farrar; R T Turner-Warwick; C G Whiteside; R C Feneley
Journal:  J Urol       Date:  1979-05       Impact factor: 7.450

6.  Prostatism. I. The correlation between symptoms, cystometric and urodynamic findings.

Authors:  J T Andersen; J Nordling; S Walter
Journal:  Scand J Urol Nephrol       Date:  1979

7.  Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.

Authors:  A Jardin; H Bensadoun; M C Delauche-Cavallier; P Attali
Journal:  Lancet       Date:  1991-06-15       Impact factor: 79.321

8.  Transurethral microwave treatment for benign prostatic hypertrophy: a randomised controlled clinical trial.

Authors:  A S Bdesha; C J Bunce; J P Kelleher; M E Snell; J Vukusic; R O Witherow
Journal:  BMJ       Date:  1993-05-15

9.  A population-based study of prostatectomy: outcomes associated with differing surgical approaches.

Authors:  N P Roos; E W Ramsey
Journal:  J Urol       Date:  1987-06       Impact factor: 7.450

10.  Symptom status and quality of life following prostatectomy.

Authors:  F J Fowler; J E Wennberg; R P Timothy; M J Barry; A G Mulley; D Hanley
Journal:  JAMA       Date:  1988-05-27       Impact factor: 56.272

View more
  2 in total

1.  Mechanisms of Lower Urinary Tract Symptoms in Pelvic Ischemia.

Authors:  Kazem M Azadzoi; Mike B Siroky
Journal:  J Biochem Pharmacol Res       Date:  2013

Review 2.  The use of lasers in benign prostatic enlargement.

Authors:  T A McNicholas; S Singh
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.